1.0893
price down icon3.47%   -0.0307
 
loading
Precedente Chiudi:
$1.12
Aprire:
$1.1
Volume 24 ore:
800.25K
Relative Volume:
0.15
Capitalizzazione di mercato:
$318.31M
Reddito:
-
Utile/perdita netta:
$-63.08M
Rapporto P/E:
-4.0344
EPS:
-0.27
Flusso di cassa netto:
$-72.53M
1 W Prestazione:
+5.99%
1M Prestazione:
+3.95%
6M Prestazione:
+38.60%
1 anno Prestazione:
-33.67%
Intervallo 1D:
Value
$1.07
$1.12
Intervallo di 1 settimana:
Value
$0.99
$1.18
Portata 52W:
Value
$0.515
$1.66

Ocugen Inc Stock (OCGN) Company Profile

Name
Nome
Ocugen Inc
Name
Telefono
484-328-4701
Name
Indirizzo
11 GREAT VALLEY PARKWAY, MALVERN, PA
Name
Dipendente
95
Name
Cinguettio
@Ocugen
Name
Prossima data di guadagno
2025-05-02
Name
Ultimi documenti SEC
Name
OCGN's Discussions on Twitter

Confronta OCGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
OCGN
Ocugen Inc
1.09 341.68M 0 -63.08M -72.53M -0.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.58 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.35 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.17 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
593.70 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
292.62 31.91B 3.81B -644.79M -669.77M -6.24

Ocugen Inc Stock (OCGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-10-15 Iniziato Maxim Group Buy
2023-03-01 Aggiornamento Chardan Capital Markets Neutral → Buy
2022-08-23 Iniziato Mizuho Buy
2022-06-15 Ripresa ROTH Capital Buy
2022-06-02 Iniziato Cantor Fitzgerald Overweight
2021-07-26 Iniziato Noble Capital Markets Outperform
2021-06-11 Downgrade ROTH Capital Buy → Neutral
2021-05-07 Downgrade Cantor Fitzgerald Overweight → Neutral
2021-02-09 Downgrade Chardan Capital Markets Buy → Neutral
2021-02-04 Aggiornamento H.C. Wainwright Neutral → Buy
Mostra tutto

Ocugen Inc Borsa (OCGN) Ultime notizie

pulisher
04:41 AM

Ocugen Inc. Stock Analysis and ForecastFree Risk Assessment Services - PrintWeekIndia

04:41 AM
pulisher
Jul 24, 2025

What risks could impact Ocugen Inc. stock performanceRapidly growing investment returns - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

What drives Ocugen Inc. stock priceStrongest growth potential - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

When is the best time to buy Ocugen Inc. stockMarket-leading growth rates - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

First Patient Dosed in Phase 2/3 GARDian3 Trial of OCU410ST for Stargardt Disease - CGTLive®

Jul 24, 2025
pulisher
Jul 24, 2025

Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN

Jul 24, 2025
pulisher
Jul 23, 2025

Ocugen, Inc. Announces New Appointments to its Retina Scientific Advisory Board and Executive Leadership Team - VisionMonday.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is Ocugen Inc. a good long term investmentRobust investment performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Ocugen Inc. stockHigh-velocity capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Ocugen announces appointments to retina scientific advisory board and executive leadership team - Ophthalmology Times

Jul 22, 2025
pulisher
Jul 21, 2025

Ocugen Bets Big On Gene Therapy Despite Major Setbacks - Finimize

Jul 21, 2025
pulisher
Jul 21, 2025

Ocugen, Inc. Announces New Appointments to Retina Scientific Adv - GuruFocus

Jul 21, 2025
pulisher
Jul 21, 2025

Ocugen expands advisory board and leadership team for gene therapy push - Investing.com India

Jul 21, 2025
pulisher
Jul 21, 2025

Ocugen, Inc. Strengthens Retina Scientific Advisory Board and Leadership Team to Advance Gene Therapy Development for Blindness Diseases - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

Ocugen Assembles Elite Gene Therapy Team: 3 Top Retina Experts Join as Company Targets Triple BLA Filing - Stock Titan

Jul 21, 2025
pulisher
Jul 21, 2025

Ocugen doses first subject in trial of modifier gene therapy candidate - Yahoo Finance

Jul 21, 2025
pulisher
Jul 19, 2025

Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy - MyChesCo

Jul 19, 2025
pulisher
Jul 18, 2025

Ocugen Announces Q2 2025 Financial Results Call and Business Update - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

Ocugen’s Phase 1 Study on OCU200: A Potential Game-Changer for Diabetic Macular Edema - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 - GuruFocus

Jul 18, 2025
pulisher
Jul 18, 2025

Ocugen doses first patient in phase 2/3 Stargardt disease trial - Investing.com Australia

Jul 18, 2025
pulisher
Jul 18, 2025

Ocugen doses first patient in phase 2/3 Stargardt disease trial By Investing.com - Investing.com South Africa

Jul 18, 2025
pulisher
Jul 18, 2025

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Revolutionary Gene Therapy Shows 48% Disease Slowdown in Stargardt Blindness Trial - Stock Titan

Jul 18, 2025
pulisher
Jul 17, 2025

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results - Ocugen

Jul 17, 2025
pulisher
Jul 17, 2025

Ocugen to Host Conference Call on Friday, August 1 at 8:30 - GlobeNewswire

Jul 17, 2025

Ocugen Inc Azioni (OCGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.29
price down icon 1.74%
$36.50
price up icon 0.00%
$103.56
price down icon 0.03%
$27.38
price down icon 0.69%
$113.86
price down icon 0.68%
biotechnology ONC
$288.37
price down icon 2.39%
Capitalizzazione:     |  Volume (24 ore):